Numerous PPAR dual/pan agonists have been developed to treat T2DM, cardiovascular diseases, dyslipidemia, obesity, hypertension, PBC, renal dysfunctions, neurological diseases, psychiatric disorders, autoimmune diseases, inflammatory diseases, malignancies, and NAFLD/NASH [9]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.